Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., Wollenhaupt, J., Kellner, H., Paramarta, J., Wei, J., Brachat, A., Bek, S., Laurent, D., Li, Y., Wang, Y. A., … Hueber, W. (2013). Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial. Lancet (London, England), 382(9906), 1705-1713. https://doi.org/10.1016/S0140-6736(13)61134-4
Baraliakos, X., Davis, J., Tsuji, W., & Braun, J. (2005). Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis and Rheumatism, 52(4), 1216-1223. https://doi.org/10.1002/art.20977
Song, I. H., Poddubnyy, D. A., Rudwaleit, M., & Sieper, J. (2008). Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism, 58(4), 929-938. https://doi.org/10.1002/art.23275
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., van Gaalen, F., Géher, P., van der Horst-Bruinsma, I., Inman, R. D., Jongkees, M., Kiltz, U., Kvien, T. K., Machado, P. M., Marzo-Ortega, H., Molto, A., … Braun, J. (2017). 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the rheumatic diseases, 76(6), 978–991. https://doi.org/10.1136/annrheumdis-2016-210770
Escalas, C., Trijau, S., & Dougados, M. (2010). Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford, England), 49(7), 1317–1325. https://doi.org/10.1093/rheumatology/keq078
Poddubnyy, D., Rudwaleit, M., Haibel, H., Listing, J., Märker-Hermann, E., Zeidler, H., Braun, J., & Sieper, J. (2012). Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the rheumatic diseases, 71(10), 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252
Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sörensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., & Braun, J. (2003). Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis and rheumatism, 48(6), 1667–1675. https://doi.org/10.1002/art.11017,
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sörensen, H., Zeidler, H., & Sieper, J. (2005). Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Annals of the rheumatic diseases, 64(2), 229–234. https://doi.org/10.1136/ard.2004.025130.
Brandt, J., Haibel, H., Cornely, D., Golder, W., Gonzalez, J., Reddig, J., Thriene, W., Sieper, J., & Braun, J. (2000). Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis and rheumatism, 43(6), 1346–1352. https://doi.org/10.1002/1529-0131(200006)43:6 , Maksymowych, W. P., Jhangri, G. S., Lambert, R. G., Mallon, C., Buenviaje, H., Pedrycz, E., Luongo, R., & Russell, A. S. (2002). Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. The Journal of rheumatology, 29(5), 959–965.
Davis, J. C., Jr, van der Heijde, D. M., Braun, J., Dougados, M., Clegg, D. O., Kivitz, A. J., Fleischmann, R. M., Inman, R. D., Ni, L., Lin, S. L., & Tsuji, W. H. (2008). Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Annals of the rheumatic diseases, 67(3), 346–352. https://doi.org/10.1136/ard.2007.078139 van der Heijde, D., Da Silva, J. C., Dougados, M., Geher, P., van der Horst-Bruinsma, I., Juanola, X., Olivieri, I., Raeman, F., Settas, L., Sieper, J., Szechinski, J., Walker, D., Boussuge, M. P., Wajdula, J. S., Paolozzi, L., Fatenejad, S., & Etanercept Study 314 Investigators (2006). Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Annals of the rheumatic diseases, 65(12), 1572–1577. https://doi.org/10.1136/ard.2006.056747 .
Baraliakos, X., Davis, J., Tsuji, W., & Braun, J. (2005). Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis and rheumatism, 52(4), 1216–1223. https://doi.org/10.1002/art.20977.
van der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., Davis, J. C., Jr, & ATLAS Study Group (2006). Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism, 54(7), 2136–2146. https://doi.org/10.1002/art.21913
Deodhar, A., Braun, J., Inman, R. D., van der Heijde, D., Zhou, Y., Xu, S., Han, C., & Hsu, B. (2015). Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Annals of the rheumatic diseases, 74(4), 757–761. https://doi.org/10.1136/annrheumdis-2014-205862, Sieper, J., van der Heijde, D., Dougados, M., Maksymowych, W. P., Scott, B. B., Boice, J. A., Berd, Y., Bergman, G., Curtis, S., Tzontcheva, A., Huyck, S., & Weng, H. H. (2015). A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis & rheumatology (Hoboken, N.J.), 67(10), 2702–2712. https://doi.org/10.1002/art.39257.
Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., Wollenhaupt, J., Kellner, H., Paramarta, J., Wei, J., Brachat, A., Bek, S., Laurent, D., Li, Y., Wang, Y. A., Bertolino, A. P., … Hueber, W. (2013). Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (London, England), 382(9906), 1705–1713. https://doi.org/10.1016/S0140-6736(13)61134-4
Poddubnyy, D., Hermann, K. G., Callhoff, J., Listing, J., & Sieper, J. (2014). Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Annals of the rheumatic diseases, 73(5), 817–823. https://doi.org/10.1136/annrheumdis-2013-204248
